Is Trident Texofab overvalued or undervalued?

As of 9 September 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive. The company is currently overvalued based on its high valuation ratios, including a PE ratio of 137.09, a Price to Book Value of 21.63, and an EV to EBITDA of 78.48. These figures suggest that the stock is trading at a significant premium compared to its earnings and book value.
In comparison to its peers, Trident Texofab's valuation appears excessive, particularly when looking at Elitecon International with a PE of 525.99 and Lloyds Enterprises at 38.79. While Trident's ROE stands at 15.77%, which is relatively strong, the overall valuation metrics indicate that the stock is not justified at its current price of 259.00. Notably, Trident Texofab has outperformed the Sensex significantly over various periods, including a staggering 512.73% return over the past year, which may have contributed to the inflated valuation.